NIH | National Cancer Institute | NCI Wiki  

Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.
Comment: Revised based on email conversation with Michael Izbicki & after seeing FDAAA phase 2 changes in Registry on UAT/Stage.

...

Note

Some fields will be accessible only to the CTRO as these fields are captured during protocol abstraction.

 

Changes in Sponsor/Responsible Party data elements:

Field Label

Description of Change

SponsorMake this field optional.
Responsible PartyMake this field optional.

 

Changes in Regulatory data elements:

Field Label

Description of Change

Trial Oversight Authority Country and Trial Oversight Authority Organization Name
Remove the fields for these data elements.
Studies a U.S. FDA-regulated Drug Product

Add this data element.

Studies a U.S. FDA-regulated Device Product

Add this data element.

Delayed Posting Indicator

Rename the field for this data element to Unapproved/Uncleared Device. Make this field optional.

Post Prior to U.S. FDA Approval or ClearanceAdd this data element.
Pediatric Post-market Surveillance

Add this data element.

Product Exported from the U.S.

Add this data element.

FDA Regulated Intervention IndicatorMake this field optional.

Section 801 Indicator

Make this field optional.

 

Changes in IND/IDE data elements:

...